Human CTLs to Wild-Type and Enhanced Epitopes of a Novel Prostate and Breast Tumor-Associated Protein, TARP, Lyse Human Breast Cancer Cells

Cancer Research

Volumn 64, Issue 7, 2004, Pages 2610-2618

  Oh, SangKon ^a,c   Terabe, Masaki ^a   Pendleton, C David ^a   Bhattacharyya, Anu ^a   Bera, Tapan K ^a   Epel, Malka ^b   Reiter, Yoram ^b   Phillips, John ^a   Linehan, W Marston ^a   Kasten Sportes, Claude ^a   Pastan, Ira ^a   Berzofsky, Jay A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; EPITOPE; HLA A2 ANTIGEN; PROTEIN TARP; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ARTICLE; BREAST CANCER; CANCER CELL; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FLOW CYTOMETRY; HLA SYSTEM; HUMAN; HUMAN CELL; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TRANSGENIC MOUSE;

AMINO ACID SEQUENCE; ANIMALS; BREAST NEOPLASMS; CANCER VACCINES; EPITOPES, T-LYMPHOCYTE; FEMALE; HLA-A2 ANTIGEN; HUMANS; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; NUCLEAR PROTEINS; PEPTIDE FRAGMENTS; PROSTATIC NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 11144357604     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-2183     Document Type: Article

References (51)

1. Correale P, Walmsley K, Zaremba S, et al. Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide. J Immunol 1998;161:3186-94.
2. Tjoa B, Boynton A, Kenny G, et al. Presentation of prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicity. Prostate 1996;28:65-9.
3. Kiessling A, Schmitz M, Stevanovic S, et al. Prostate stem cell antigen: identification of immunogenic peptides and assessment of reactive CD8+ T cells in prostate cancer patients. Int J Cancer 2002;102:390-7.
4. Peshwa MV, Shi JD, Ruegg C, Laus R, van Schooten WC. Induction of prostate tumor-specific CD8+ cytotoxic T-lymphocytes in vitro using antigen-presenting cells pulsed with prostatic acid phosphatase peptide. Prostate 1998:36:129-38.
5. Elzey BD. Siemens DR, Ratliff TL, Lubaroff DM. Immunization with type 5 adenovirus recombinant for a tumor antigen in combination with recombinant canarypox virus (ALVAC) cytokine gene delivery induces destruction of established prostate tumors. Int J Cancer 2001:94:842-9.
6. Gulley J, Chen AP, Dahut W, et al. Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. Prostate 2002;53:109-17.
7. Murphy GP. Tjoa BA, Simmons SJ. et al. Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a Phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. Prostate 1999;38:73-8.
8. Small EJ, Fratesi P, Reese DM, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000;18:3894-903.
9. Brinkmann U, Vasmatzis G, Lee B, et al. PAGE-1, an X chromosome-linked GAGE-like gene that is expressed in normal and neoplastic prostate, testis, and uterus. Proc Natl Acad Sci USA 1998;95:10757-62.
10. Olsson P, Bera TK, Essand M. et al. GDEP, a new gene differentially expressed in normal prostate and prostate cancer. Prostate 2001;48:231-41.
11. Bera TK, lavarone C, Kumar V, et al. MRP9, an unusual truncated member of the ABC transporter superfamily, is highly expressed in breast cancer. Proc Natl Acad Sci USA 2002;99:6997-7002.
12. Essand M, Vasmatzis G, Brinkmann U, et al. High expression of a specific T-cell receptor γ transcript in epithelial cells of the prostate. Proc Natl Acad Sci USA 1999;96:9297-92.
13. Wolfgang CD, Essand M, Vincent JJ, Lee B, Pastan I. TARP: a nuclear protein expressed in prostate and breast cancer cells derived from an alternate reading frame of the T cell receptor γ chain locus. Proc Natl Acad Sci USA 2000;97:9437-42.
14. Stamey TA, Warrington JA, Caldwell MC, et al, Molecular genetic profiling of Gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia. J Urol 2001;166:2171-7.
15. Ernst T, Hergenhahn M, Kenzelmann M, et al. Decrease and gain of gene expression are equally discriminatory markers for prostate carcinoma: a gene expression analysis on total and microdissected prostate tissue. Am J Pathol 2002;160:2169-80.
16. Best CJ, Leiva IM, Chuaqui RF, et al. Molecular differentiation of high- and moderate-grade human prostate cancer by cDNA microarray analysis. Diagn Mol Pathol 2003;12:63-70.
17. Sherman LA, Hesse SV, Irwin MJ, La Face D, Peterson P. Selecting T cell receptors with high affinity for self-MHC by decreasing the contribution of CD8. Science (Wash. DC) 1992;258:815-8.
18. Berzofsky JA. Epitope selection and design of synthetic vaccines: molecular approaches to enhancing immunogenicity and crossreactivity of engineered vaccines. Ann N Y Acad Sci 1993;690:256-64.
19. Berzofsky JA, Ahlers JD, Belyakov IM. Strategies for designing and optimizing new generation vaccines. Nat Rev Immunol 2001;1:209-19.
20. Sarobe P, Pendleton CD, Akatsuka T, et al. Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A2.1 binding positions. J Clin Investig 1998;102:1239-48.
21. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998;4:321-7.
22. Zaremba S, Barzaga E, Zhu M, et al. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Cancer Res 1997;57:4570-7.
23. Okazaki T, Pendleton DC, Lemonnier F, Berzofsky JA. Epitope-enhanced conserved HIV-1 peptide protects HLA-A2-transgenic mice against virus expressing HIV-1 antigen. J Immunol 2003;171:2548-55.
24. Alexander MA, Damico CA, Wieties KM, Hansen TH, Connolly JM. Correlation between CD8 dependency and determinant density using peptide-induced, Ld-restricted cytotoxic T lymphocytes. J Exp Med 1991;173:849-58.
25. Wolfgang CD, Essand M, Lee B, Pastan I. T-cell receptor γ chain alternate reading frame protein (TARP) expression in prostate cancer cells leads to an increased growth rate and induction of caveolins and amphiregulin. Cancer Res 2001;61:8122-6.
26. Nijman HW, Houbiers JGA, Vierboom MPM, et al. Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes. Eur J Immunol 1993;23:1215-9.
27. Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD Jr. Peptide-pulsed dendritic cells induce antigen-specific, CTL-mediated protective tumor immunity. J Exp Med 1996;183:283-7.
28. Oh S, Hodge JW, Ahlers JD, et al. Selective induction of high avidity CTL by altering the balance of signals from antigen presenting cells. J Immunol 2003;170:2523-30.
29. Altman JD, Moss PAH, Goulder PJR, et al. Phenotypic analysis of antigen-specific T lymphocytes. Science (Wash. DC) 1996;274:94-6.
30. Denkberg G, Cohen CJ. Lev A, et al. Direct visualization of distinct T cell epitopes derived from a melanoma tumor-associated antigen by using human recombinant antibodies with MHC-restricted T cell receptor-like specificity. Proc Natl Acad Sci USA 2002;99:9421-6.
31. Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 1994;152:163-75.
32. Gotch FM, Rothbard J. Howland K, Townsend ARM, McMichael AJ. Cytotoxic T lymphocytes recognize a fragment of influenza virus matrix protein in association with HLA-A2. Nature (Lond.) 1987;326:881-2.
33. Ruppert J, Sidney J, Celis E. et al. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell 1993;74:929-37.
34. Bouvier M, Wiley DC. Importance of peptide amino and carboxyl termini to the stability of MHC class I molecules. Science (Wash. DC) 1994;265:398-402.
35. Rammensee H-G, Friede T, Stevanovíc S. MHC ligands and peptide motifs: first listing. Immunogenetics 1995;41:178-228.
36. Shirai M, Arichi T, Nishioka M, et al. CTL responses of HLAA2.1-transgenic mice specific for hepatitis C viral peptides predict epitopes for CTL of humans carrying HLA-2.1. J Immunol 1995;154:2733-42.
37. Terasawa H, Tsang KY, Gulley J, Arlen P, Schlom J. Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen. Clin Cancer Res 2002;8:41-53.
38. Sette A, Vitiello A, Reherman B, et al. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol 1994;153:5586-92.
39. Bakker AB, van der Burg SH, Huijbens RJ, et al. Analogues of CTL epitopes with improved MHC class-I binding capacity elicit anti-melanoma CTL recognizing the wild-type epitope. Int J Cancer 1997;70:302-9.
40. Pietersz GA, Li W, Osinski C, Apostolopoulos V, McKenzie IF. Definition of MHC-restricted CTL epitopes from non-variable number of tandem repeat sequence of MUCI. Vaccine 2000;18:2059-71.
41. Tallquist MD, Yun TJ, Pease LR. A single T cell receptor recognizes structurally distinct MHC/peptide complexes with high specificity. J Exp Med 1996;184:1017-26.
42. Loftus DJ, Chen Y, Covell DG, Engelhard VH, Appella E. Differential contact of disparate class 1/peptide complexes as the basis for epitope cross-recognition by a single T cell receptor. J Immunol 1997;158:3651-8.
43. Shirai M, Vacchio MS, Hodes RJ, Berzofsky JA. Preferential Vb usage by cytotoxic T cells crossreactive between two epitopes of HIV-1 gp160 and degenerate in class I MHC restriction. J Immunol 1993;151:2283-95.
44. Brock R, Wiesmüller K-H, Jung G, Walden P. Molecular basis for the recognition of two structurally different major histocompatibility complex/peptide complexes by a single T-cell receptor. Proc Natl Acad Sci USA 1996;93:13108-13.
45. Shirai M, Kurokohchi K, Pendleton CD, et al. Reciprocal CTL cross-reactivity interactions between two major epitopes within HIV-1 gp160. J Immunol 1996;157:4399-411.
46. Wilson CS, Moser JM, Altman JD, Jensen PE, Lukacher AE. Cross-recognition of two middle T protein epitopes by immunodominant polyoma virus-specific CTL. J Immunol 1999;162:3933-41.
47. Lev A, Denkberg G, Cohen CJ, et al. Isolation and characterization of human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells directed toward the widely expressed tumor T-cell epitopes of the telomerase catalytic subunit. Cancer Res 2002;62:3184-94.
48. Cohen CJ, Hoffmann N, Farago M, et al. Direct detection and quantitation of a distinct T-cell epitope derived from tumor-specific epithelial cell-associated mucin using human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells. Cancer Res 2002;62:5835-44.
49. Cohen CJ, Sarig O, Yamano Y, et al. Direct phenotypic analysis of human MHC class I antigen presentation: visualization, quantitation, and in situ detection of human viral epitopes using peptide-specific, MHC-restricted human recombinant antibodies. J Immunol 2003;170:4349-61.
50. Porgador A, Yewdell JW, Deng Y, Bennink JR, Germain RN. Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. Immunity 1997;6:715-26.
51. d complexed with an antigenic peptide: similarities to a T cell receptor with the same specificity. J Immunol 2000;165:5703-12.